Limits...
Dual targeted therapy with p53 siRNA and Epigallocatechingallate in a triple negative breast cancer cell model.

Braicu C, Pileczki V, Pop L, Petric RC, Chira S, Pointiere E, Achimas-Cadariu P, Berindan-Neagoe I - PLoS ONE (2015)

Bottom Line: Gene expression analysis revealed 28 genes were significantly altered (16 upregulated and 12 downregulated) in response to combined p53 siRNA and EGCG treatment.Further analysis revealed that p53 siRNA and EGCG dual therapy leads to the activation of pro-apoptotic genes and the inhibition of pro-survival genes, autophagy, and cell network formation.These results indicate that this dual therapy targets both the apoptotic and angiogenic pathways, which may improve treatment effectiveness for tumors resistant to conventional treatment.

View Article: PubMed Central - PubMed

Affiliation: Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

ABSTRACT
Triple-negative breast cancer (TNBC) is a highly aggressive phenotype that is resistant to standard therapy. Thus, the development of alternative therapeutic strategies for TNBC is essential. The purpose of our in vitro study was to evaluate the impact of p53 gene silencing in conjunction with the administration of a natural compound, epigallocatechingallate (EGCG). RT2Profiler PCR Array technology was used to evaluate the impact of dual treatment on the main genes involved in apoptosis in the Hs578T cell culture model of TNBC. Gene expression analysis revealed 28 genes were significantly altered (16 upregulated and 12 downregulated) in response to combined p53 siRNA and EGCG treatment. Further analysis revealed that p53 siRNA and EGCG dual therapy leads to the activation of pro-apoptotic genes and the inhibition of pro-survival genes, autophagy, and cell network formation. These results indicate that this dual therapy targets both the apoptotic and angiogenic pathways, which may improve treatment effectiveness for tumors resistant to conventional treatment.

No MeSH data available.


Related in: MedlinePlus

Autophagy evaluation.Microscopical evaluation was done in the presence of the selected treatment scenarios at 24 and 48 h post-treatment in Hs578T cell line.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4388814&req=5

pone.0120936.g004: Autophagy evaluation.Microscopical evaluation was done in the presence of the selected treatment scenarios at 24 and 48 h post-treatment in Hs578T cell line.

Mentions: Figs 3 and 4 show the effect of p53 gene knockdown and combined treatment with EGCG in blocking angiogenesis and autophagy. Hs578T cell network formation was significantly reduced in the cells treated with EGCG for 24 and 48 h, respectively, compared with control-treated cells.


Dual targeted therapy with p53 siRNA and Epigallocatechingallate in a triple negative breast cancer cell model.

Braicu C, Pileczki V, Pop L, Petric RC, Chira S, Pointiere E, Achimas-Cadariu P, Berindan-Neagoe I - PLoS ONE (2015)

Autophagy evaluation.Microscopical evaluation was done in the presence of the selected treatment scenarios at 24 and 48 h post-treatment in Hs578T cell line.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4388814&req=5

pone.0120936.g004: Autophagy evaluation.Microscopical evaluation was done in the presence of the selected treatment scenarios at 24 and 48 h post-treatment in Hs578T cell line.
Mentions: Figs 3 and 4 show the effect of p53 gene knockdown and combined treatment with EGCG in blocking angiogenesis and autophagy. Hs578T cell network formation was significantly reduced in the cells treated with EGCG for 24 and 48 h, respectively, compared with control-treated cells.

Bottom Line: Gene expression analysis revealed 28 genes were significantly altered (16 upregulated and 12 downregulated) in response to combined p53 siRNA and EGCG treatment.Further analysis revealed that p53 siRNA and EGCG dual therapy leads to the activation of pro-apoptotic genes and the inhibition of pro-survival genes, autophagy, and cell network formation.These results indicate that this dual therapy targets both the apoptotic and angiogenic pathways, which may improve treatment effectiveness for tumors resistant to conventional treatment.

View Article: PubMed Central - PubMed

Affiliation: Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

ABSTRACT
Triple-negative breast cancer (TNBC) is a highly aggressive phenotype that is resistant to standard therapy. Thus, the development of alternative therapeutic strategies for TNBC is essential. The purpose of our in vitro study was to evaluate the impact of p53 gene silencing in conjunction with the administration of a natural compound, epigallocatechingallate (EGCG). RT2Profiler PCR Array technology was used to evaluate the impact of dual treatment on the main genes involved in apoptosis in the Hs578T cell culture model of TNBC. Gene expression analysis revealed 28 genes were significantly altered (16 upregulated and 12 downregulated) in response to combined p53 siRNA and EGCG treatment. Further analysis revealed that p53 siRNA and EGCG dual therapy leads to the activation of pro-apoptotic genes and the inhibition of pro-survival genes, autophagy, and cell network formation. These results indicate that this dual therapy targets both the apoptotic and angiogenic pathways, which may improve treatment effectiveness for tumors resistant to conventional treatment.

No MeSH data available.


Related in: MedlinePlus